HLS.TOライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 04:05):

Stats
本日の出来高	700.00
平均出来高	9 848.00
時価総額	148.43M
EPS	$-0.170 ( 2024-03-14 )
次の収益日	( $-0.250 ) 2024-05-08
Last Dividend	$0.0500 ( 2023-04-27 )
Next Dividend	$0 ( N/A )
P/E	-3.97
ATR14	$0 (0.00%)

HLS THERAPEUTICS INC 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

HLS THERAPEUTICS INC 財務諸表

Annual	2023
収益:	$63.07M
総利益:	$55.45M (87.91 %)
EPS:	$-0.850

FY	2023
収益:	$63.07M
総利益:	$55.45M (87.91 %)
EPS:	$-0.850

FY	2022
収益:	$61.47M
総利益:	$56.49M (91.90 %)
EPS:	$-0.730

FY	2021
収益:	$60.01M
総利益:	$56.04M (93.38 %)
EPS:	$-0.410

Financial Reports:

No articles found.

HLS THERAPEUTICS INC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.0500 (N/A)	$0.0500 (N/A)	$0.0500 (N/A)	$0.0500 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

HLS THERAPEUTICS INC Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.14 - low (4.63%) | Divividend Growth Potential Score: 1.423 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0500	2019-01-30
Last Dividend	$0.0500	2023-04-27
Next Dividend	$0	N/A
Payout Date	2023-06-15
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	$0.900	--
Avg. Dividend % Per Year	0.75%	--
Score	2.66	--
Div. Sustainability Score	3.14
Div.Growth Potential Score	1.423
Div. Directional Score	2.28	--

Next Divdend (Est)
(2024-07-01)

$0.0509 Estimate 10.00 %

Dividend Stability

0.40 Below Average

Dividend Score

2.66

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2019	$0.200	1.43%
2020	$0.200	0.81%
2021	$0.200	1.18%
2022	$0.200	1.36%
2023	$0.100	0.99%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for TSX

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
XLB.TO	Dividend Knight	2023-08-25	Monthly	19	1.89%
PZA.TO	Dividend Royal	2023-09-28	Monthly	20	4.10%
FM.TO	Dividend Junior	2023-08-25	Semi-Annually	20	0.32%
ABST.TO	Dividend Knight	2023-05-10	Quarterly	12	1.37%
VBAL.TO	Dividend Junior	2023-07-05	Quarterly	7	1.11%
MR-UN.TO	Dividend King	2023-09-28	Monthly	12	4.52%
CYH.TO	Dividend King	2023-09-25	Monthly	17	2.68%
XTD.TO	Dividend King	2023-08-30	Monthly	18	6.61%
RQN.TO	Dividend Knight	2023-08-23	Monthly	6	1.43%
GXE.TO	Dividend King	2023-09-14	Monthly	3	3.72%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.436	1.500	-8.73	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.132	1.200	-4.39	-5.27	[0 - 0.3]
returnOnEquityTTM	-0.256	1.500	-3.96	-5.94	[0.1 - 1]
payoutRatioTTM	-0.0871	-1.000	-0.871	0.871	[0 - 1]
currentRatioTTM	1.652	0.800	6.74	5.39	[1 - 3]
quickRatioTTM	1.223	0.800	7.51	6.01	[0.8 - 2.5]
cashRatioTTM	0.823	1.500	6.54	9.81	[0.2 - 2]
debtRatioTTM	0.419	-1.500	3.01	-4.52	[0 - 0.6]
interestCoverageTTM	-1.143	1.000	-1.534	-1.534	[3 - 30]
operatingCashFlowPerShareTTM	0.501	2.00	9.83	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.499	2.00	9.75	10.00	[0 - 20]
debtEquityRatioTTM	0.897	-1.500	6.41	-9.62	[0 - 2.5]
grossProfitMarginTTM	0.879	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.159	1.000	-5.17	-5.17	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.180	1.000	-0.110	-0.110	[0.2 - 2]
assetTurnoverTTM	0.302	0.800	-1.322	-1.058	[0.5 - 2]
Total Score				3.14

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-3.90	1.000	-0.495	0	[1 - 100]
returnOnEquityTTM	-0.256	2.50	-2.54	-5.94	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.499	2.00	9.83	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.501	2.00	9.83	10.00	[0 - 30]
payoutRatioTTM	-0.0871	1.500	-0.871	0.871	[0 - 1]
pegRatioTTM	0.115	1.500	-2.56	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.250	1.000	6.24	0	[0.1 - 0.5]
Total Score				1.423

HLS THERAPEUTICS INC

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.